[Skip to content]

Print this page
.

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240;  241-260 261-280; 281-300; 301-320; 341-360; 361-380

 

NICE TAs 321-340

 

REF

 

TITLE

 

DHFT Formulary link

 

East Midlands Cancer Network link (cancer drugs only)

TA 321           Dabrafenib - skin cancer    EMCN algorithm
TA 322

 Lenalidomide for treating myelodysplastic syndromes

   EMCN algorithm
TA 323

Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy

9.1.2 - 9.1.6 Megaloblastic, hypoplastic, haemolytic and renal anaemias 

 

TA 324

Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block

 

No drug implications
TA 325

Nalmefene for reducing alcohol consumption in people with alcohol dependence

4.10 Substance abuse

 

TA 326

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours

  EMCN guidelines
EMCN algorithm
TA 327

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism.

  2.8 Anticoagulants

 
 TA328

Idelasilib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal)

Not recommended by NICE

 
 TA329

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

1.5 Treatment of chronic diarrhoeas

 
 TA330

Sofosbuvir for treating chronic hepatitis C

5.3.3 Viral Hepatitis

 
 TA331

Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C

 5.3.3 Viral Hepatitis

 
 TA332

Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer

Not recommended by NICE

 
 TA333            

Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment

   EMCN guidelines
 TA334 

Regorafenib for metastatic colorectal cancer after treatment for metastatic disease

Not recommended by NICE

 
 TA335             

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

2.8.2 Oral anticoagulants

 

 
 TA336

Empagliflozin in combination therapy for treating type 2 diabetes 

6.1.2.3 Other anti-diabetics 

 
 TA337

Rifaximin for preventing episodes of overt hepatic encephalopathy

5.1.7 Antibacterial: Some other antibiotics, trimethoprim, antituberculous drugs

 
 TA338

Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib

  Not approved; available only via CDF
 TA339

Omalizumab for previously treated chronic spontaneous urticaria

3.4.2 Allergen Immunotherapy

 
 TA340

Ustekinumab for treating active psoriatic arthritis

10.1.3 Drugs which suppress the rheumatic disease process